Vera Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for immunological diseases, with a particular focus on IgA nephropathy (IgAN) and lupus nephritis (LN). Their lead investigational product, Atacicept, is a novel biologic therapy designed as a recombinant fusion protein that targets the soluble TACI receptor. This mechanism allows Atacicept to bind to the cytokines BAFF and APRIL, which are known to stimulate B cells and plasma cells, leading to the production of autoantibodies associated with these diseases. Clinical trials have demonstrated that Atacicept can stabilize estimated glomerular filtration rate (eGFR) and reduce markers of disease activity, such as Gd-IgA1 levels and proteinuria, indicating its potential as a disease-modifying treatment.

The company is currently conducting pivotal Phase 3 clinical trials for Atacicept in patients with IgAN, aiming to address the significant unmet medical need for effective therapies in this area. The drug has shown a favorable safety profile and can be administered via a once-weekly subcutaneous injection, making it a convenient option for patients. Vera Therapeutics holds exclusive worldwide rights for the development and commercialization of Atacicept across all indications, underscoring their commitment to advancing treatment options for patients suffering from these serious immunological conditions.

United States

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Immune System Diseases

Kidney Diseases

Vera Therapeutics

IgA nephropathy

Atacicept

Lupus nephritis

Atacicept 

BK virus

Kidney transplantation

<p class="font_8">MAU868 has the potential to neutralize infection by blocking BKV virions &nbsp;from binding to host cells. MAU868 is currently undergoing a &nbsp;randomized, double-blind, placebo-controlled Phase 2 clinical trial to &nbsp;assess the safety, pharmacokinetics, and efficacy for the treatment of &nbsp;BKV in kidney transplant patients. Vera holds an exclusive worldwide &nbsp;license for the development and commercialization of MAU868 in all &nbsp;indications acquired from Amplyx Pharmaceuticals, Inc., a wholly owned &nbsp;subsidiary of Pfizer Inc.</p>

Vera Therapeutics

Company Details